行情

MACK

MACK

Merrimack Pharma
NASDAQ

实时行情|Nasdaq Last Sale

3.450
-0.010
-0.29%
交易中 15:31 04/08 EDT
开盘
3.770
昨收
3.460
最高
3.770
最低
3.407
成交量
9.68万
成交额
--
52周最高
5.51
52周最低
1.490
市值
4,616.18万
市盈率(TTM)
-2.1663
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MACK价格均价为4.000,最高价位4.000,最低价为4.000。

EPS

MACK 新闻

更多
  • Merrimack Pharma Reports Receipt Of $2.25M Related To Closing Of Asset Sale For Preclinical Nanoliposome Programs To Celator Pharma
  • Benzinga · 6天前
  • Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update
  • Business Wire · 6天前
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37

所属板块

生物技术和医学研究
+3.27%
制药与医学研究
+3.29%

热门股票

代码
价格
涨跌幅

MACK 简况

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.
展开

微牛提供Merrimack Pharmaceuticals Inc(NASDAQ-MACK)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MACK股票新闻,以帮助您做出投资决策。